Wedbush Reiterates “Outperform” Rating for Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA)

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA)‘s stock had its “outperform” rating restated by equities researchers at Wedbush in a research note issued to investors on Friday,Benzinga reports. They presently have a $35.00 price target on the stock. Wedbush’s target price would suggest a potential upside of 65.96% from the stock’s current price.

Several other brokerages also recently issued reports on DMRA. Royal Bank Of Canada started coverage on Damora Therapeutics, Inc. Common Stock in a research note on Friday, April 24th. They set an “outperform” rating and a $40.00 target price on the stock. Evercore assumed coverage on Damora Therapeutics, Inc. Common Stock in a research note on Wednesday, March 25th. They issued an “outperform” rating and a $46.00 price target for the company. TD Cowen initiated coverage on shares of Damora Therapeutics, Inc. Common Stock in a report on Monday. They set a “buy” rating for the company. HC Wainwright assumed coverage on shares of Damora Therapeutics, Inc. Common Stock in a research report on Thursday. They set a “buy” rating and a $45.00 price objective on the stock. Finally, Guggenheim reissued a “buy” rating and issued a $40.00 target price (up from $36.00) on shares of Damora Therapeutics, Inc. Common Stock in a report on Tuesday, February 17th. Two investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Damora Therapeutics, Inc. Common Stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $42.43.

Damora Therapeutics, Inc. Common Stock Stock Down 1.3%

DMRA stock traded down $0.27 during trading on Friday, reaching $21.09. The company’s stock had a trading volume of 32,439 shares, compared to its average volume of 272,964. Damora Therapeutics, Inc. Common Stock has a 1 year low of $2.45 and a 1 year high of $38.33. The company has a market capitalization of $1.30 billion, a P/E ratio of -3.78 and a beta of 1.46. The company’s fifty day moving average is $24.59 and its 200-day moving average is $25.37.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.23). Analysts anticipate that Damora Therapeutics, Inc. Common Stock will post -2.13 earnings per share for the current year.

Institutional Investors Weigh In On Damora Therapeutics, Inc. Common Stock

Hedge funds have recently made changes to their positions in the company. Janus Henderson Group PLC bought a new position in Damora Therapeutics, Inc. Common Stock during the fourth quarter valued at approximately $40,000. Geode Capital Management LLC bought a new stake in Damora Therapeutics, Inc. Common Stock in the 4th quarter worth approximately $266,000. Virtu Financial LLC purchased a new stake in shares of Damora Therapeutics, Inc. Common Stock during the 3rd quarter worth approximately $49,000. Sigma Planning Corp purchased a new stake in shares of Damora Therapeutics, Inc. Common Stock during the 4th quarter worth approximately $334,000. Finally, Two Sigma Investments LP bought a new position in shares of Damora Therapeutics, Inc. Common Stock during the 3rd quarter valued at approximately $76,000. 14.20% of the stock is currently owned by hedge funds and other institutional investors.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.